10-Q: Integrated BioPharma Q3 2026 Financial Results

Integrated BioPharma reports a net loss of $0.8 million for the third quarter of 2026 amid declining sales and high customer concentration.

Summary

• Net sales for the third quarter ended March 31, 2026, were $10.1 million, a 27.5% decrease compared to $13.9 million in the same period last year.
• The company reported a net loss of $0.8 million for the quarter, compared to a net income of $0.6 million in the prior year period.
• For the nine months ended March 31, 2026, net sales were $34.1 million, down 15.2% from $40.2 million in the prior year.
• Operating loss for the nine months ended March 31, 2026, was $1.8 million, compared to an operating income of $1.4 million in the prior year.
• Cash and cash equivalents increased to $5.8 million as of March 31, 2026, from $3.6 million at June 30, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the significant decline in revenue, the shift to operating losses, and the high concentration risk that threatens future stability.

Positives

• Cash position improved to $5.8 million as of March 31, 2026.
• Successfully renewed and extended the PNC Bank credit facility.
• Maintained stable selling and administrative expenses despite revenue headwinds.

Negatives

• Significant decline in net sales across both Contract Manufacturing and Other Business Lines segments.
• Gross profit turned into a loss of $0.3 million for the quarter.
• High customer concentration risk, with two customers accounting for 90% of consolidated net sales.
• Operating loss of $1.8 million for the nine-month period.

Risks

• Extreme reliance on two major customers for the majority of revenue.
• Inflationary pressures and tariffs impacting operating margins.
• Tightened labor markets and potential for increased labor costs.
• Exposure to union contract negotiations expiring August 31, 2026.
• Inability to pass on increased costs to customers in a timely manner.

Future Outlook

The company is focusing on improving operational efficiency and reducing spending to manage expense levels and gross margins. Management aims to expand the customer base to reduce reliance on the two significant customers, though they caution that actual results may differ from expectations due to economic conditions and competitive pressures.

Management Comments

• Management is focusing efforts to improve operational efficiency and reduce spending.
• Management believes that current operations and the revolving credit facility will support working capital requirements through May 8, 2027.

Industry Context

StockSavvy.ai notes that the nutraceutical and contract manufacturing sectors are currently facing significant margin compression due to persistent inflationary pressures and supply chain volatility. Integrated BioPharma's struggle with customer concentration is a common vulnerability in the mid-market contract manufacturing space, where the loss of a single key account can disproportionately impact quarterly performance.

Comparison to Industry Standards

• The company's reliance on two customers for 90% of revenue is significantly higher than the industry standard for diversified contract manufacturers.
• Operating margins have deteriorated compared to historical performance and broader industry benchmarks for the nutraceutical manufacturing sector.

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that would have a material adverse effect on its business.

Related Party Transactions

• Lease agreements with Vitamin Realty Associates, LLC, which is controlled by the Co-Chief Executive Officers and their mother.

Stakeholder Impact

• Shareholders face increased risk due to declining profitability and high customer concentration.
• Employees are subject to upcoming union contract negotiations.
• Customers may face price increases as the company attempts to offset inflationary costs.

Next Steps

• Continue efforts to expand the customer base.
• Monitor union contract negotiations ahead of the August 31, 2026 expiration.
• Manage capital expenditures within the $200,000 budget for the remainder of fiscal year 2026.

Key Dates

Recommendation

The combination of a significant revenue decline, operating losses, and extreme customer concentration creates a high-risk profile that outweighs the current cash position, suggesting a cautious or bearish outlook for investors.

Keywords

Integrated BioPharma, Contract Manufacturing, Nutraceuticals, Vitamins, Financial Results, 10-Q